AI vs. high blood pressure: smart software aims to personalize treatment

NCT ID NCT06828692

Recruiting now Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether artificial intelligence (AI) can help doctors in China pick better blood pressure medications for their patients. Over 2,000 adults with high blood pressure will be treated at primary care clinics. Some clinics will use AI software that considers patient data and guidelines, while others will use standard care. The goal is to see if the AI tools help more patients reach their blood pressure targets faster and with fewer medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Clinical decision support system (CDSS) using machine learning and hemodynamic profiles
What this could lead to: If successful, this could provide doctors with a practical AI tool to personalize blood pressure medications, leading to better control and fewer complications.
What could go wrong: This is a pragmatic trial in primary care, so results may vary by setting. The AI tools may not outperform usual care, and the study is not designed to prove long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Locations

Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences
RECRUITING

Shenzhen, Shenzhen, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.